BMA
LLY icon

Brooks Moore & Associates’s Eli Lilly LLY Stock Holding History

Brooks Moore & Associates’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.38M Buy
2,819
+195
+7% +$199K 1.52% 20
2026
Q1 		$2.41M Sell
2,624
-200
-7% -$203K 1.21% 28
2025
Q4 		$3.03M Sell
2,824
-354
-11% -$338K 1.49% 23
2025
Q3 		$2.42M Buy
3,178
+35
+1% +$26K 1.23% 26
2025
Q2 		$2.33M Sell
3,143
-115
-4% -$89.4K 1.26% 26
2025
Q1 		$2.69M Hold
3,258
– – 1.52% 25
2024
Q4 		$2.52M Sell
3,258
-110
-3% -$91.1K 1.49% 26
2024
Q3 		$2.98M Sell
3,368
-552
-14% -$496K 1.76% 21
2024
Q2 		$3.55M Buy
3,920
+184
+5% +$147K 2.28% 17
2024
Q1 		$2.91M Sell
3,736
-50
-1% -$35.6K 1.86% 19
2023
Q4 		$2.21M Sell
3,786
-36
-0.9% -$21K 1.52% 28
2023
Q3 		$2.05M Sell
3,822
-748
-16% -$385K 1.55% 27
2023
Q2 		$2.14M Sell
4,570
-104
-2% -$43.6K 1.51% 27
2023
Q1 		$1.6M Buy
4,674
+11
+0.2% +$3.71K 1.15% 32
2022
Q4 		$1.71M Sell
4,663
-51
-1% -$18.1K 1.25% 33
2022
Q3 		$1.52M Hold
4,714
– – 1.23% 33
2022
Q2 		$1.53M Sell
4,714
-709
-13% -$213K 1.1% 35
2022
Q1 		$1.55M Sell
5,423
-250
-4% -$64.3K 0.95% 37
2021
Q4 		$1.57M Sell
5,673
-128
-2% -$32.4K 0.92% 40
2021
Q3 		$1.34M Sell
5,801
-100
-2% -$24.7K 0.88% 42
2021
Q2 		$1.35M Hold
5,901
– – 0.86% 42
2021
Q1 		$1.1M Buy
5,901
+1,500
+34% +$293K 0.75% 44
2020
Q4 		$743K Hold
4,401
– – 0.58% 47
2020
Q3 		$651K Sell
4,401
-42
-0.9% -$6.5K 0.56% 50
2020
Q2 		$729K Buy
4,443
+348
+8% +$53.4K 0.68% 48
2020
Q1 		$568K Sell
4,095
-574
-12% -$78.9K 0.6% 54
2019
Q4 		$614K Hold
4,669
– – 0.49% 63
2019
Q3 		$522K Sell
4,669
-451
-9% -$50.2K 0.44% 67
2019
Q2 		$567K Sell
5,120
-926
-15% -$109K 0.49% 65
2019
Q1 		$785K Buy
6,046
+130
+2% +$15.8K 0.72% 51
2018
Q4 		$685K Buy
+5,916
New +$661K 0.69% 52

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Brooks Moore & Associates's LLY Position: Q2 2026 in Review

Brooks Moore & Associates increased its Eli Lilly (LLY) stake by 7.4% in Q2 2026, buying an estimated $199K and bringing the position to 2,819 shares worth $3.38M. The position accounts for 1.52% of the portfolio, ranked #20.

Brooks Moore & Associates first reported a position in LLY in Q4 2018 and has held it in 31 quarters since. The position peaked at $3.55M in Q2 2024. 4,630 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Brooks Moore & Associates held 2,819 shares of Eli Lilly worth $3.38M as of Q2 2026.
  • Brooks Moore & Associates bought 195 Eli Lilly shares in Q2 2026, an estimated $199K.
  • Eli Lilly made up 1.52% of Brooks Moore & Associates's portfolio in Q2 2026, its #20 holding.
  • Brooks Moore & Associates first reported a position in Eli Lilly in Q4 2018 and has held it in 31 quarters since.
  • Brooks Moore & Associates's Eli Lilly position peaked at $3.55M in Q2 2024.
  • 4,630 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Brooks Moore & Associates's 13F filing for Q2 2026, filed 17 Aug 2026.